Nautilus Biotechnology (NAUT) Amortizatization of Intangibles (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Amortizatization of Intangibles of -$12000.0 for Q2 2026, down 117.65% sequentially from $68000.0 in Q1 2026, and down 102.73% YoY from $439000.0 in Q2 2025.
Nautilus Biotechnology (NAUT) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Amortizatization of Intangibles for 7 years, with the latest figure at -$12000.0 in Q2 2026.
- Quarterly Amortizatization of Intangibles fell 102.73% year-over-year to -$12000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $496000.0 (down 78.72% YoY) and the FY2025 annual result came in at $1.4 million, down 49.36% from the prior year.
- Amortizatization of Intangibles slipped to -$12000.0 in Q2 2026 per NAUT's latest filing, from $68000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $751000.0 in Q1 2024 and troughed at -$26000.0 in Q1 2022.
- A 5-year average of $434944.4 and a median of $545500.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2026: Amortizatization of Intangibles soared 7757.14% in 2022, then plunged 102.73% in 2026.
- Over 5 years, Amortizatization of Intangibles stood at $550000.0 in 2022, then rose by 12.55% to $619000.0 in 2023, then grew by 1.45% to $628000.0 in 2024, then plunged by 78.66% to $134000.0 in 2025, then slumped by 108.96% to -$12000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$12000.0, $68000.0, and $134000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | 1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12,000.00 |
| Jun 30, 2026 | -12,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 306,000.00 |
| Sep 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 439,000.00 |
| Jun 30, 2025 | 439,000.00 |
| Mar 31, 2025 | 541,000.00 |
| Mar 31, 2025 | 541,000.00 |
| Dec 31, 2024 | 628,000.00 |
| Dec 31, 2024 | 628,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Jun 30, 2024 | 702,000.00 |
| Jun 30, 2024 | 702,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Mar 31, 2024 | 751,000.00 |